Compare Roblox Corp (RBLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Roblox Corp trades at $49.6 (market cap $37.59B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| RBLX | XBI | |
|---|---|---|
Market Cap | $37.59B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $141.56 | $164.28 |
52-Week Low | $41.30 | $85.16 |
Enterprise Value | $36.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox trades at $52.50, up 1.59% with neutral technical signals. The company shows strong revenue growth reaching $4.89B in 2025 but continues to report significant losses with a -20.69% net margin. Analyst consensus is bullish with a $59.62 price target, though multiple class action lawsuits filed in July 2026 create near-term uncertainty. Operating cash flow improved to $1.8B, supporting ongoing platform investments.
Roblox presents a growth investment case with expanding user engagement and AI innovation, but profitability challenges and legal risks require careful monitoring. The stock offers 13.6% upside to consensus target, though high P/S ratio of 7.03 and negative ROE of -295.16% highlight valuation concerns amid persistent losses.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
